The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Elisabetta AbruzzeseDuring the European School of Hematology (ESH) 3rd How to Diagnose and Treat: CML/MPN conference, the MPN Hub was pleased to speak to Elisabetta Abruzzese, Sant’Eugenio Hospital, Rome, IT. We asked, What are the key considerations in managing pregnancy in myeloproliferative neoplasms (MPN)?
What are the key considerations in managing pregnancy in MPN?
Elisabetta Abruzzese opens by discussing the increased need for effective treatment strategies for pregnant patients with MPN. Increasing rates of early diagnosis during reproductive years combined with the general trend of later pregnancies both contribute to this need. Abruzzese goes on to outline the risks associated with pregnancy in MPN, including thrombosis and hemorrhage both during and post-partum. The indication for additional therapies to reduce these risks as opposed to discontinuing any current treatment is noted. The interview concludes with a discussion on the appropriate therapeutics for use in essential thrombocytopenia, polycythemia vera, and myelofibrosis.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content